About Tobora
Precision medicine for
rheumatoid arthritis.
Tobora AS is a Norwegian health-tech company based in Oslo, dedicated to improving treatment outcomes for patients with rheumatoid arthritis (RA) through machine learning and clinical research.
We collaborate with leading institutions—including Diakonhjemmet Sykehus and the University of Oslo—to develop prediction models that identify optimal treatment strategies at baseline, eliminating costly trial-and-error approaches.
Our mission is to close the remission gap: the 50–60% of RA patients who fail to achieve remission with standard first-line therapy deserve better, faster answers.
Get in touch
Contact
For research collaborations, investment inquiries, or general questions—we'd love to hear from you.
[email protected]Tobora AS
Oslo, Norway
Why it matters
RA care still depends too much on trial and error.
Rheumatoid arthritis treatment has advanced dramatically, yet many patients still move through months of uncertainty before finding an effective therapy. That delay can mean persistent inflammation, worsening fatigue and function, and avoidable pressure on specialist services.
Tobora focuses on the decision point before escalation becomes obvious: using baseline and early clinical signals to support a more precise first treatment strategy.
What we build
Decision support shaped by clinical reality.
Clinical prediction
Models that estimate treatment response earlier, so therapy decisions can be more individualized from the start.
Patient-reported outcomes
Structured use of symptom burden, function, fatigue, sleep, and well-being measures alongside clinical markers.
Validation and translation
Research workflows designed for clinical scrutiny, reproducibility, and eventual use in real-world care pathways.
How we work
Research rigor, product clarity.
Clinically grounded and product-minded.
Transparent enough for research partners to challenge.
Useful at the point where treatment choices are actually made.
We work with clinical partners to make sure model development is tied to meaningful endpoints, practical workflows, product usability, and the questions rheumatologists actually face when choosing therapy.